GROSSO ® Reshaper FIH Trial: Enrollment Update and Clinical Progress

The GROSSO ® Reshaper First-In-Human (FIH) study continues to advance its clinical evaluation, with four patients already successfully recruited and treated at the IMO Grupo Miranza in Barcelona, Spain.

Up to 2 months follow up, these treatments showed excellent safey profile and promising data of anatomical efficacy with evidence of a corneal regularization effect in the areas where the GROSSO ® Reshaper is present. The completion of these procedures marks a significant phase in the trial's progression, establishing a preliminary clinical foundation as the study prepares to extend its enrollment activities to additional clinical sites.